VIR-2218
Phase 2Small molecule
VIR-2218 is one of 17 small molecule programs targeting Hepatitis D, Chronic. It is currently in Phase 2.
2
Indications
10
Total Trials
2
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Chronic Hepatitis B Virus Infection
#DrugCompanyPhaseTrials
1Emtriva
GileadApproved
Hepsera
GileadApproved
Cerubidine
HHikma Pharmaceuticals LLC
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Alinia
RRomark Laboratories L.C.
Approved
Virazole
CConrado Roberto Hoffmann Filho
Approved
Bepirovirsen
GSKPhase 2
PEG-IFNα
GileadPhase 2
VIR-3434
VVir Biotechnology, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis4 trials
Chronic Hepatitis B Virus Infection2 trials
Renal Impairment1 trial
Hepatic Impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VIR-2218. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVir Biotechnology, Inc.